

Product Data Sheet

Product Name: Remigromig

Cat. No.: GC81344

Chemical Properties

Cas. No. 3059389-31-7

Formula M.Wt 199.68

Solubility Storage Store at -20°C

General tips For obtaining a higher solubility , please warm the tube at 37 °C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Shipping Condition Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request.

Structure

Remigromig

Background

Remigromig (EYE-103; MK-3000) is a humanized dual-target monoclonal antibody that targets LRP5 and FZD4. Remigromig activates the Wnt/ β -catenin signaling pathway by mimicking the natural ligand Norrin, induces tight junction formation and restores blood-retinal barrier function. Administered via intravitreal injection, Remigromig reduces retinal vascular leakage, and demonstrates improvements in best-corrected visual acuity and reductions in retinal thickness in studies of diabetic macular edema. Remigromig can be used for research related to macular degeneration [1].

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

In Vivo, Intravitreally administered Remigromig demonstrates effects of reducing retinal vascular leakage, improving best-corrected visual acuity, and decreasing retinal thickness in studies of diabetic macular edema and neovascular age-related macular degeneration^[1].

In Vitro, Remigromig activates the Wnt/ β -catenin signaling pathway by mimicking the natural ligand Norrin, induces tight junction formation in endothelial cells, and enhances the function of the blood-retinal barrier^[1].

References:

[1]. Shirian JD, et al. Exploring new horizons in neovascular age-related macular degeneration: novel mechanisms of action and future therapeutic avenues. Eye (London, England). 2025 Jan;39(1):40-44.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA